GILEAD SCIENCES INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
GILEAD SCIENCES INC. - More news...
GILEAD SCIENCES INC. - More news...
- Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
- Gilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth
- Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
- FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
- Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
- Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
- Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
- Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
- Gilead Sciences Supports the LGBTQ+ Community in Oakland: Love Is the Answer
- Asian American Women Engineers Find Community and Purpose at Gilead
- Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
- Gilead Sciences: Living with a Rare Blood Cancer: Marion’s Story
- AbTherx Announces License Agreement with Gilead
- Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
- Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
- Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
- Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
- Bilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer
- CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
- Gilead Sciences to Present at Upcoming Investor Conference
- How Gilead’s Supportive Culture Helps Working Parents: LJ’s Story
- Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
- Gilead Appoints Cindy Perettie Executive Vice President of Kite
- Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
- Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
- Gilead Emphasizes Unique Ways To Hire Top Talent
- Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
- CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
